KRAS and colorectal carcinoma: Advancements in treatment armamentarium of CRC, such as immunotherapy and RAS inhibitors (targeting KRAS G12C, panKRAS, and panRAS inhibitors), may affect the prognosis and management of EOCRC patients in the near future.26